Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2025
Event: Entry into a Material Definitive Agreement (Credit Agreement).
Key Financial Metrics and Debt Structure
This filing details the establishment of a new credit facility rather than reporting operational financial results (revenue, profit, or cash flow) for the period.
- Facility Size: $500.0 million revolving line of credit.
- Letter of Credit Sublimit: $150.0 million.
- Interest Rate: Base rate, term SOFR, or alternative currency term rate plus an applicable margin of 1.50% to 2.50% (based on Total Leverage Ratio).
- Commitment Fee: 0.20% to 0.35% per annum on unused commitments.
- Maturity Date: September 30, 2030 (subject to acceleration under specific "Springing Maturity Debt" conditions).
- Collateral: Secured by substantially all assets of the Company and material domestic subsidiaries.
Material Changes and Covenants
The Company entered into a new Credit Agreement with Bank of America, N.A., as Administrative Agent. The agreement imposes specific financial covenants that must be maintained at the end of each fiscal quarter:
- Total Net Leverage Ratio: Must be less than or equal to 3.75:1.00. This ratio may step up by 0.50:1.00 for four fiscal quarters following a Material Acquisition.
- Consolidated Interest Coverage Ratio: Must be greater than or equal to 3.00:1.00.
The filing does not provide comparative financial data (e.g., revenue or profit changes) versus prior periods as it is a transactional report.
Outlook, Risks, and Management Commentary
Use of Proceeds: Working capital and general corporate purposes.
Incremental Capacity: The Company has the right to incur incremental revolving commitments or term loans, subject to customary conditions, though lenders are not obligated to provide them.
Risks and Contingencies:
- Acceleration Risk: The Maturity Date may be accelerated to 91 days prior to the maturity of "Springing Maturity Debt" if outstanding principal exceeds the greater of $630.0 million or 100% of Consolidated EBITDA, unless specific liquidity or leverage thresholds are met.
- Covenant Compliance: Failure to maintain the required leverage or interest coverage ratios constitutes an event of default.
Investor Verification Checklist
- Verify the Company's current Total Net Leverage Ratio and Consolidated Interest Coverage Ratio to ensure compliance with the new 3.75:1.00 and 3.00:1.00 covenants.
- Review the definition of "Springing Maturity Debt" and assess if existing debt structures could trigger an acceleration of the new facility's maturity date.
- Confirm the status of any outstanding letters of credit deemed issued under this new agreement.
- Monitor future filings for any "Material Acquisition" that would temporarily adjust the leverage ratio covenant.